The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Validation of the Zebrafish Pentylenetetrazol Seizure Model: Locomotor versus Electrographic Responses to Antiepileptic Drugs
Open accessAbstract
Zebrafish have recently emerged as an attractive in vivo model for epilepsy. Seven-day-old zebrafish larvae exposed to the GABA(A) antagonist pentylenetetrazol (PTZ) exhibit increased locomotor activity, seizure-like behavior, and epileptiform electrographic activity. A previous study showed that 12 out of 13 antiepileptic drugs (AEDs) suppressed PTZ-mediated increases in larval movement, indicating the potential utility of zebrafish as a high-throughput in vivo model for AED discovery. However, a question remained as to whether an AED-induced decrease in locomotion is truly indicative of anticonvulsant activity, as some drugs may impair larval movement through other mechanisms such as general toxicity or sedation. We therefore carried out a study in PTZ-treated zebrafish larvae, to directly compare the ability of AEDs to inhibit seizure-like behavioral manifestations with their capacity to suppress epileptiform electrographic activity. We re-tested the 13 AEDs of which 12 were previously reported to inhibit convulsions in the larval movement tracking assay, administering concentrations that did not, on their own, impair locomotion. In parallel, we carried out open-field recordings on larval brains after treatment with each AED. For the majority of AEDs we obtained the same response in both the behavioral and electrographic assays. Overall our data correlate well with those reported in the literature for acute rodent PTZ tests, indicating that the larval zebrafish brain is more discriminatory than previously thought in its response to AEDs with different modes of action. Our results underscore the validity of using the zebrafish larval locomotor assay as a rapid first-pass screening tool in assessing the anticonvulsant and/or proconvulsant activity of compounds, but also highlight the importance of performing adequate validation when using in vivo models.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Standards for epidemiologic studies and surveillance of epilepsy
Thurman, D. J., Beghi, E., Begley, C. E., Berg, A. T., Buchhalter, J. R., Ding, D., Hesdorffer, D. C., Hauser, W. A., Kazis, L., Kobau, R., et al. (2011) · Epilepsia · doi:10.1111/j.1528-1167.2011.03121.x · Cited by 1,014
Löscher, W. (2011) · Seizure · doi:10.1016/j.seizure.2011.01.003 · Cited by 932
Pentylenetetrazole induced changes in zebrafish behavior, neural activity and c-fos expression
Baraban, S. C., Taylor, M. R., Castro, P. A., & Baier, H. (2005) · Neuroscience · doi:10.1016/j.neuroscience.2004.11.031 · Cited by 687
Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy
Klitgaard, H., Matagne, A., Gobert, J., & Wülfert, E. (1998) · European Journal of Pharmacology · doi:10.1016/s0014-2999(98)00410-5 · Cited by 506
Topiramate: Preclinical Evaluation of a Structurally Novel Anticonvulsant
Shank, R. P., Gardocki, J. F., Vaught, J. L., Davis, C. B., Schupsky, J. J., Raffa, R. B., Dodgson, S. J., Nortey, S. O., & Maryanoff, B. E. (1994) · Epilepsia · doi:10.1111/j.1528-1157.1994.tb02459.x · Cited by 345
The Neuropharmacology of the Ketogenic Diet
Hartman, A. L., Gasior, M., Vining, E. P. G., & Rogawski, M. A. (2007) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2007.02.008 · Cited by 325
Löscher, W., & Hönack, D. (1993) · European Journal of Pharmacology · doi:10.1016/0014-2999(93)90768-d · Cited by 281
Berghmans, S., Hunt, J., Roach, A., & Goldsmith, P. (2007) · Epilepsy Research · doi:10.1016/j.eplepsyres.2007.03.015 · Cited by 266
ucb L059, a novel anti-convulsant drug: pharmacological profile in animais
Gower, A. J., Noyer, M., Verloes, R., Gobert, J., & Wülfert, E. (1992) · European Journal of Pharmacology · doi:10.1016/0014-2999(92)90855-x · Cited by 212
Mandhane, S. N., Aavula, K., & Rajamannar, T. (2007) · Seizure · doi:10.1016/j.seizure.2007.05.005 · Cited by 179
Cited by
Baraban, S. C., Dinday, M. T., & Hortopan, G. A. (2013) · Nature Communications · doi:10.1038/ncomms3410 · Cited by 436
Fontana, B. D., Mezzomo, N. J., Kalueff, A. V., & Rosemberg, D. B. (2018) · Experimental Neurology · doi:10.1016/j.expneurol.2017.10.004 · Cited by 272
Suls, A., Jaehn, J. A., Kecskés, A., Weber, Y., Weckhuysen, S., Craiu, D. C., Siekierska, A., Djémié, T., Afrikanova, T., Gormley, P., et al. (2013) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2013.09.017 · Cited by 219
Self-citationIdentification of GSK-3 as a potential therapeutic entry point for epilepsy.
Aourz, N., Serruys, A.-S. K., Chabwine, J. N., Balegamire, P. B., Afrikanova, T., Edrada-Ebel, R., Grey, A. I., Kamuhabwa, A. R., Walrave, L., Esguerra, C. V., et al. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00281 · Cited by 49
Self-citation
Metadata
- Authors
- Afrikanova, T., Serruys, A.-S. K., Buenafe, O. E. M., Clinckers, R., Smolders, I., de Witte, P. A. M., Crawford, A. D., & Esguerra, C. V.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2013-01-14
- Volume
- 8
- Issue
- 1
- Pages
- e54166
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W1981307673
- Cited by
- 279
- References
- 28
- FWCI
- 7.66
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Validation of the Zebrafish Pentylenetetrazol Seizure Model: Locomotor versus Electrographic Responses to Antiepileptic Drugs. https://app.cochat.ai/papers/10.1371/journal.pone.0054166
- The paper
- Afrikanova, T., Serruys, A.-S. K., Buenafe, O. E. M., Clinckers, R., Smolders, I., de Witte, P. A. M., Crawford, A. D., & Esguerra, C. V. (2013). Validation of the Zebrafish Pentylenetetrazol Seizure Model: Locomotor versus Electrographic Responses to Antiepileptic Drugs. PLoS ONE. https://doi.org/10.1371/journal.pone.0054166
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.